Sertraline
A double-blind placebo RCT assessed if oral sertraline (50 mg/day) can contribute to preserving the hearing threshold among patients with lymphoma and gastric cancer exposed to cisplatin. The two groups were distributed homogeneously. The ototoxicity grade for the sertraline group was lower compared to the placebo group (p<0.001). The level of distortion product otoacoustic emissions was unchanged among 57.1% in the sertraline group versus 17.1% in the placebo group (p=0.000). However, 11.4% of the patients in the sertraline group reported severe nausea and vomiting (Delarestaghi et al., 2018).